C5specific

C5specific is a term used in immunology and pharmacology to describe reagents and therapies that specifically target the complement component C5. These agents, typically monoclonal antibodies or engineered proteins, bind with high affinity to C5 in the circulation and prevent its proteolytic cleavage by C5 convertase. As a result, production of the inflammatory mediator C5a and the assembly of the membrane attack complex C5b-9 are inhibited, reducing complement-mediated inflammation and cell lysis.

In clinical practice, C5-specific therapies are used to treat diseases driven by uncontrolled terminal complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH) and atypative hemolytic uremic syndrome (aHUS), as well as certain antibody-mediated neuroinflammatory conditions. The best-known examples are the monoclonal antibodies eculizumab and ravulizumab, both designed to bind human C5 and block its activation. Additional C5-targeted agents have been developed or are in development, with varying half-lives and dosing schedules to improve convenience for patients.

Safety considerations include an increased risk of meningococcal infections due to impaired terminal complement activity; vaccination and prophylactic measures are recommended. Long-term suppression of terminal complement activity requires monitoring for breakthrough hemolysis and other infections, as well as assessment of cost and access issues.

Terminology: the phrase "C5-specific" or "C5specific" emphasizes selectivity for C5 over other components of the complement cascade, such as C3 or C1q. See also: complement system, C5 convertase, membrane attack complex.